Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 9Skin Neoplasms 2Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Healthy Volunteer 1Healthy Adults 1Glioblastoma 1Eye Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

montanide ISA 51 2Interleukin-2 2binimetinib 1belinostat 1Vincristine 1Tramadol 1Topotecan 1Proton Therapy 1Peptides 1Melphalan 1Magnetic Resonance Spectroscopy 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Lasers 1Laparotomy 1Ibuprofen 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Etoposide 1Doxorubicin 1D-methadone 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Eye Neoplasms × Peptides × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡